Precision BioSciences (DTIL) Metrics: History & Chart

Precision BioSciences, Inc.(DTIL)

Biotechnology · Durham, NC

$6.20-0.11 (-1.74%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.

Durham, NC

67 employees

www.precisionbiosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Amoroso

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+1.12%
30D Total Return	-15.53%
YTD Total Return	+51.68%
1Y Total Return	+15.99%
3Y Total Return	-33.08%
5Y Total Return	-98.12%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+51.68%
2025	+9.19%
2024	-65.21%
2023	-69.33%
2022	-83.92%
2021	-11.27%
2020

CAGR TTM	+15.91%
CAGR 3Y	-12.53%
CAGR 5Y	-54.84%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	2.81
PE Ratio Avg TTM	12.61
PE Ratio Avg 3Y	12.61
Current VS TTM Avg	-77.71%
Current VS 3Y Avg	-77.71%
Current VS 5Y Avg	-77.71%

All Metrics

DTIL Valuation Metrics

DTIL Stock Price Metrics

DTIL Dividend Metrics

DTIL Growth Rate Metrics

DTIL Discounted Cash Flow Metrics

DTIL Returns By Period

DTIL Yearly Returns

DTIL Average Annual Returns By Period (CAGR)

DTIL Revenue Metrics

DTIL PE Ratio Metrics

DTIL PS Ratio Metrics

DTIL PB Ratio Metrics

DTIL Price to Free Cash Flow Ratio Metrics

DTIL Debt to Equity Ratio Metrics

DTIL PEG Ratio Metrics

DTIL FCF Yield

DTIL Earnings Yield

DTIL EBITDA Yield

DTIL OCF Yield

DTIL EV/EBIT Ratio Metrics

DTIL EV/EBITDA Ratio Metrics

DTIL EV/Assets Ratio Metrics

DTIL EV/Sales Ratio Metrics

DTIL Current Ratio Metrics

DTIL Quick Ratio Metrics

DTIL ROIC Metrics

DTIL Return on Assets Metrics

DTIL Return on Equity Metrics

DTIL Net Profit Margin Metrics

DTIL Gross Profit Margin Metrics

DTIL Tax Rate Metrics

PS Ratio	3.62
PS Ratio Avg TTM	34.48
PS Ratio Avg 3Y	1.54
Current VS TTM Avg	-89.50%
Current VS 3Y Avg	+135.55%
Current VS 5Y Avg	+58.08%

PB Ratio	3.60
PB Ratio Avg TTM	2.82
PB Ratio Avg 3Y	1.70
Current VS TTM Avg	+27.59%
Current VS 3Y Avg	+111.74%
Current VS 5Y Avg	+119.88%

PFCF Ratio	431.20
PFCF Ratio Avg TTM	396.65
PFCF Ratio Avg 3Y	396.65
Current VS TTM Avg	+8.71%
Current VS 3Y Avg	+8.71%
Current VS 5Y Avg	+8.71%

Debt/Equity Ratio	0.62
Debt/Equity Ratio Avg TTM	0.78
Debt/Equity Ratio Avg 3Y	0.61
Current VS TTM Avg	-20.92%
Current VS 3Y Avg	+2.40%
Current VS 5Y Avg	+34.06%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	0.23%
FCF Yield Avg TTM	0.25%
FCF Yield Avg 3Y	0.25%
Current VS TTM Avg	-9.32%
Current VS 3Y Avg	-9.32%
Current VS 5Y Avg	-9.32%

Earnings Yield	35.60%
Earnings Yield Avg TTM	7.73%
Earnings Yield Avg 3Y	7.73%
Current VS TTM Avg	+360.76%
Current VS 3Y Avg	+360.76%
Current VS 5Y Avg	+360.76%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.84
Ev/Assets Ratio Avg TTM	0.59
Ev/Assets Ratio Avg 3Y	0.53
Current VS TTM Avg	+42.91%
Current VS 3Y Avg	+58.34%
Current VS 5Y Avg	+43.29%

Ev/Sales Ratio	2.33
Ev/Sales Ratio Avg TTM	23.43
Ev/Sales Ratio Avg 3Y	22.39
Current VS TTM Avg	-90.06%
Current VS 3Y Avg	-89.60%
Current VS 5Y Avg	-77.54%

Current Ratio	12.82
Current Ratio Avg TTM	9.76
Current Ratio Avg 3Y	6.80
Current VS TTM Avg	+31.41%
Current VS 3Y Avg	+88.55%
Current VS 5Y Avg	+178.81%

Quick Ratio	12.82
Quick Ratio Avg TTM	9.76
Quick Ratio Avg 3Y	6.80
Current VS TTM Avg	+31.41%
Current VS 3Y Avg	+88.55%
Current VS 5Y Avg	+178.81%

ROIC	(30.23%)
ROIC Avg 3Y	(25.84%)
ROIC Avg 5Y	(29.40%)
Current VS 3Y Avg	-16.99%
Current VS 5Y Avg	-2.83%
Current VS 10Y Avg	+10.26%

ROA	(41.88%)
ROA Avg TTM	(14.12%)
ROA Avg 3Y	(13.28%)
Current VS TTM Avg	-196.67%
Current VS 3Y Avg	-215.39%
Current VS 5Y Avg	-256.92%

ROE	(116.42%)
ROE Avg TTM	(191.14%)
ROE Avg 3Y	(151.96%)
Current VS TTM Avg	+39.09%
Current VS 3Y Avg	+23.39%
Current VS 5Y Avg	+13.12%

Net Profit Margin	(117.04%)
Net Profit Margin Avg TTM	(59650.98%)
Net Profit Margin Avg 3Y	(604.76%)
Current VS TTM Avg	+99.80%
Current VS 3Y Avg	+80.65%
Current VS 5Y Avg	+43.64%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	80.00%
Gross Pft Margin Avg 3Y	100.00%
Current VS TTM Avg	+25.00%
Current VS 3Y Avg	0.00%
Current VS 5Y Avg	+6.23%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A